Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Dose Comparison in Advanced GIST
NCT00009906Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2000
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Survival up to 3 years, Progression-Free Survival up to 3 years and 1 more. Started Dec 2000; status: terminated.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00009906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00009906.